Ozmosi | Auranofin Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Auranofin

Alternative Names: auranofin, ridaura
Clinical Status: Inactive
Latest Update: 2025-08-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TR Inhibitor, NF-KB Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Canada | Colombia | Germany | India | Ireland | Italy | New Zealand | Norway | Pakistan | Peru | Portugal | Slovenia | South Africa | Sweden | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

05/25/2021

News Article

 Seidor and Hub OS Partner Together to Bring Automation to the Hotel Operations in the US

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions